Patrick M. Forde
Johns Hopkins University · 560 works · 23,136 citations · h-index 67
Top works
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- Genome-wide cell-free DNA fragmentation in patients with cancer
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- Ipilimumab-induced immune-related renal failure--a case report.
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
- Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- Detection and characterization of lung cancer using cell-free DNA fragmentomes
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
- PD-1 Blockade in Anaplastic Thyroid Carcinoma
- Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
- LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
- Neoadjuvant Chemoimmunotherapy for NSCLC